» Articles » PMID: 31842810

Preoperative Plasma Fatty Acid Metabolites Inform Risk of Prostate Cancer Progression and May Be Used for Personalized Patient Stratification

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2019 Dec 18
PMID 31842810
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Little is known about the relationship between the metabolite profile of plasma from pre-operative prostate cancer (PCa) patients and the risk of PCa progression. In this study we investigated the association between pre-operative plasma metabolites and risk of biochemical-, local- and metastatic-recurrence, with the aim of improving patient stratification.

Methods: We conducted a case-control study within a cohort of PCa patients recruited between 1996 and 2015. The age-matched primary cases (n = 33) were stratified in low risk, high risk without progression and high risk with progression as defined by the National Comprehensive Cancer Network. These samples were compared to metastatic (n = 9) and healthy controls (n = 10). The pre-operative plasma from primary cases and the plasma from metastatic patients and controls were assessed with untargeted metabolomics by LC-MS. The association between risk of progression and metabolite abundance was calculated using multivariate Cox proportional-hazard regression and the relationship between metabolites and outcome was calculated using median cut-off normalized values of metabolite abundance by Log-Rank test using the Kaplan Meier method.

Results: Medium-chain acylcarnitines (C6-C12) were positively associated with the risk of PSA progression (p = 0.036, median cut-off) while long-chain acylcarnitines (C14-C16) were inversely associated with local (p = 0.034) and bone progression (p = 0.0033). In primary cases, medium-chain acylcarnitines were positively associated with suberic acid, which also correlated with the risk of PSA progression (p = 0.032, Log-Rank test). In the metastatic samples, this effect was consistent for hexanoylcarnitine, L.octanoylcarnitine and decanoylcarnitine. Medium-chain acylcarnitines and suberic acid displayed the same inverse association with tryptophan, while indoleacetic acid, a breakdown product of tryptophan metabolism was strongly associated with PSA (p = 0.0081, Log-Rank test) and lymph node progression (p = 0.025, Log-Rank test). These data were consistent with the increased expression of indoleamine 2,3 dioxygenase (IDO1) in metastatic versus primary samples (p = 0.014). Finally, functional experiments revealed a synergistic effect of long chain fatty acids in combination with dihydrotestosterone administration on the transcription of androgen responsive genes.

Conclusions: This study strengthens the emerging link between fatty acid metabolism and PCa progression and suggests that measuring levels of medium- and long-chain acylcarnitines in pre-operative patient plasma may provide a basis for improving patient stratification.

Citing Articles

Acylcarnitine Profiling in Meningiomas with Different NF2 Mutation Statuses.

Bogusiewicz J, Furtak J, Birski M, Soszynska K, Majdanska A, Ryfa A Int J Mol Sci. 2025; 26(4).

PMID: 40004036 PMC: 11855264. DOI: 10.3390/ijms26041570.


Targeted Metabolic Profiling in Determining the Metabolic Heterogeneity in Human Biopsies of Different Grades of Glioma.

Vanisree A, Thamizhoviya G, Thiruvalluvan A Mol Neurobiol. 2024; 62(4):4377-4390.

PMID: 39446218 DOI: 10.1007/s12035-024-04538-1.


Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors.

Chen J, Liu J, Liu J, She L, Zou T, Yang F J Immunother Cancer. 2024; 12(7).

PMID: 38991728 PMC: 11243122. DOI: 10.1136/jitc-2024-009399.


Urinary fatty acid biomarkers for prostate cancer detection.

Noriega Landa E, Quaye G, Su X, Badmos S, Holbrook K, Polascik T PLoS One. 2024; 19(2):e0297615.

PMID: 38335180 PMC: 10857612. DOI: 10.1371/journal.pone.0297615.


Palmitic acid-activated GPRs/KLF7/CCL2 pathway is involved in the crosstalk between bone marrow adipocytes and prostate cancer.

Wang J, Liu J, Yuan C, Yang B, Pang H, Chen K BMC Cancer. 2024; 24(1):75.

PMID: 38221626 PMC: 10789002. DOI: 10.1186/s12885-024-11826-5.


References
1.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

2.
Pettaway C, Pathak S, Greene G, Ramirez E, Wilson M, Killion J . Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res. 1996; 2(9):1627-36. View

3.
Chandran U, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W . Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007; 7:64. PMC: 1865555. DOI: 10.1186/1471-2407-7-64. View

4.
Mohler J, Bahnson R, Boston B, Busby J, DAmico A, Eastham J . NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8(2):162-200. DOI: 10.6004/jnccn.2010.0012. View

5.
Prendergast G . Cancer: Why tumours eat tryptophan. Nature. 2011; 478(7368):192-4. DOI: 10.1038/478192a. View